SCHEMBL14737746

SCHEMBL14737746

FC1(F)CCN(CCCCl)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.38
SLC6A4 P31645 1/20 0.34
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
HRH1 P35367 1/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
OPRM1 P35372 2/20 0.32
FGFR1 P11362 2/20 0.31
FGFR2 P21802 2/20 0.31
FGFR4 P22455 2/20 0.31
FGFR3 P22607 2/20 0.31
KDR P35968 2/20 0.31
S1PR4 O95977 1/20 0.30
S1PR1 P21453 1/20 0.30
S1PR3 Q99500 1/20 0.30
S1PR5 Q9H228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2957084 0.87 CYP3A4 (0.31) HRH3CYP3A4CYP2D6HRH1
Hydrochloric Acid SCHEMBL1877995 0.85 CYP3A4 (0.30) CYP3A4CYP2D6HRH1
Hydrochloric Acid SCHEMBL4363063 0.85 HRH3 (0.45) HRH3SLC6A4CYP2D6HRH1NOS3
SCHEMBL31370616 0.81 HRH3 (0.45) HRH3SLC6A4CYP2D6HRH1NOS3
SCHEMBL14921181 0.81 HRH3 (0.35) HRH3SLC6A4CYP3A4CYP2D6HRH1
SCHEMBL4489186 0.79 HRH3 (0.34) HRH3SLC6A4NOS3NOS1NOS2
SCHEMBL4489191 0.79 HRH3 (0.34) HRH3SLC6A4NOS3NOS1NOS2
SCHEMBL2672697 0.79 KEAP1 (0.42) HRH3SLC6A4CYP2D6NOS3NOS1
SCHEMBL9946182 0.79 S1PR1 (0.47) OPRM1S1PR4S1PR1S1PR3S1PR5
Bromide SCHEMBL31466403 0.78 CYP3A4 (0.31) CYP3A4CYP2D6HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
CN-103102345-B Aminoquinazoline derivative, salts thereof and application method GUANGDONG HEC PHARMACEUTICAL 2015-06-03 CN disclosed
CN-104024258-A Pyrrolopyrazine kinase inhibitors HOFFMANN LA ROCHE 2014-09-03 CN disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 EP disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 HRH3 2710/4885SLC6A4 4815/4885CYP3A4 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.